207 related articles for article (PubMed ID: 36091021)
1. Integrative analyses identify HIF-1α as a potential protective role with immune cell infiltration in adamantinomatous craniopharyngioma.
Gao Q; Luo J; Pan J; Zhang L; Song D; Zhang M; Xu D; Guo F
Front Immunol; 2022; 13():949509. PubMed ID: 36091021
[TBL] [Abstract][Full Text] [Related]
2. Identification and Functional Enrichment Analysis of Potential Diagnostic and Therapeutic Targets in Adamantinomatous Craniopharyngioma.
Zou YF; Meng LB; Wang QQ; He ZK; Hu CH; Shan MJ; Wang DY; Yu X
J Comput Biol; 2020 Jan; 27(1):55-68. PubMed ID: 31424286
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles reveal key genes for early diagnosis and treatment of adamantinomatous craniopharyngioma.
Yang J; Hou Z; Wang C; Wang H; Zhang H
Cancer Gene Ther; 2018 Oct; 25(9-10):227-239. PubMed ID: 29681617
[TBL] [Abstract][Full Text] [Related]
4. Single-cell RNA sequencing highlights intratumor heterogeneity and intercellular network featured in adamantinomatous craniopharyngioma.
Jiang Y; Yang J; Liang R; Zan X; Fan R; Shan B; Liu H; Li L; Wang Y; Wu M; Qi X; Chen H; Ren Q; Liu Z; Wang Y; Zhang J; Zhou P; Li Q; Tian M; Yang J; Wang C; Li X; Jiang S; Zhou L; Zhang G; Chen Y; Xu J
Sci Adv; 2023 Apr; 9(15):eadc8933. PubMed ID: 37043580
[TBL] [Abstract][Full Text] [Related]
5. Integrative Analysis of Biomarkers and Mechanisms in Adamantinomatous Craniopharyngioma.
Lin D; Zhao W; Yang J; Wang H; Zhang H
Front Genet; 2022; 13():830793. PubMed ID: 35432485
[TBL] [Abstract][Full Text] [Related]
6. Hub genes for early diagnosis and therapy of adamantinomatous craniopharyngioma.
Zou YF; Zhang SY; Li LW; Jing K; Xia L; Sun CX; Wu B
Medicine (Baltimore); 2022 Sep; 101(37):e30278. PubMed ID: 36123899
[TBL] [Abstract][Full Text] [Related]
7. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis.
Prince EW; Apps JR; Jeang J; Chee K; Medlin S; Jackson EM; Dudley R; Limbrick D; Naftel R; Johnston J; Feldstein N; Prolo LM; Ginn K; Niazi T; Smith A; Kilburn L; Chern J; Leonard J; Lam S; Hersh DS; Gonzalez-Meljem JM; Amani V; Donson AM; Mitra SS; Bandopadhayay P; Martinez-Barbera JP; Hankinson TC
Neuro Oncol; 2024 Jun; 26(6):1109-1123. PubMed ID: 38334125
[TBL] [Abstract][Full Text] [Related]
9. Identification and Characterization of TF-lncRNA Regulatory Networks Involved in the Tumorigenesis and Development of Adamantinomatous Craniopharyngioma.
Xu D; Guo Y; Lei S; Guo A; Song D; Gao Q; Zhao S; Yin K; Wei Q; Zhang L; Wang X; Wang J; Zhang Q; Guo F
Front Oncol; 2021; 11():739714. PubMed ID: 35155179
[TBL] [Abstract][Full Text] [Related]
10. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
Esheba GE; Hassan AA
J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
[TBL] [Abstract][Full Text] [Related]
11. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
Hengartner AC; Prince E; Vijmasi T; Hankinson TC
Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1α leads to growth hormone deficiency in adamantinomatous craniopharyngioma by targeting pericytes: implication in pituitary fibrosis.
Mao J; Qiu B; Mei F; Liu F; Feng Z; Fan J; Nie J; Huang L; Liao X; Wang Z; Zeng J; Weng Z; Zang N; Qi S; Bao Y
Metabolism; 2019 Dec; 101():153998. PubMed ID: 31666193
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional analyses of adult and pediatric adamantinomatous craniopharyngioma reveals similar expression signatures regarding potential therapeutic targets.
Prince E; Whelan R; Donson A; Staulcup S; Hengartner A; Vijmasi T; Agwu C; Lillehei KO; Foreman NK; Johnston JM; Massimi L; Anderson RCE; Souweidane MM; Naftel RP; Limbrick DD; Grant G; Niazi TN; Dudley R; Kilburn L; Jackson EM; Jallo GI; Ginn K; Smith A; Chern JJ; Lee A; Drapeau A; Krieger MD; Handler MH; Hankinson TC;
Acta Neuropathol Commun; 2020 May; 8(1):68. PubMed ID: 32404202
[TBL] [Abstract][Full Text] [Related]
14. Relative quantitative expression of hypoxia-inducible factor 1α messenger ribonucleic acid in recurrent craniopharyngiomas.
Liu H; Liu Z; Li J; Li Q; You C; Xu J
Neurol India; 2014; 62(1):53-6. PubMed ID: 24608455
[TBL] [Abstract][Full Text] [Related]
15. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
Martinez-Barbera JP
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
[TBL] [Abstract][Full Text] [Related]
16. Immune infiltration in aggressive papillary craniopharyngioma: High infiltration but low action.
Jia Y; Ma L; Cai K; Zhang B; Wu W; Xiao Y; Qiao N; Ru S; Cao L; Gao H; Gui S
Front Immunol; 2022; 13():995655. PubMed ID: 36389809
[TBL] [Abstract][Full Text] [Related]
17. The molecular pathogenesis of craniopharyngiomas.
Campanini ML; Almeida JP; Martins CS; de Castro M
Arch Endocrinol Metab; 2023 Mar; 67(2):266-275. PubMed ID: 36748936
[TBL] [Abstract][Full Text] [Related]
18. High expression levels of CXCL12 and CXCR4 predict recurrence of adamanti-nomatous craniopharyngiomas in children.
Gong J; Zhang H; Xing S; Li C; Ma Z; Jia G; Hu W
Cancer Biomark; 2014; 14(4):241-51. PubMed ID: 24934367
[TBL] [Abstract][Full Text] [Related]
19. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
20. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
Robinson LC; Santagata S; Hankinson TC
Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
